| Wenjing Wang, MD | |
|
302 Lauman Ave, Eagleville, PA 19403-1626 | |
| (610) 631-8167 | |
| Not Available |
| Full Name | Wenjing Wang |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 38 Years |
| Location | 302 Lauman Ave, Eagleville, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508051012 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | MD427641 (Pennsylvania) | Secondary |
| 207ZC0500X | Pathology - Cytopathology | 25MA08747700 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Morristown Pathology Associates Pa | 4981699717 | 29 |
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
One person dies of it every 30 seconds, it rivals HIV and tuberculosis as the world's most deadly infection and the vast majority of its victims are under five years old.
Today, UK charity Action on Hearing Loss announces a major investment to fund a new project to develop medicines to treat age-related hearing loss and noise-induced hearing loss at BioTrinity 2016 – Europe's Leading Investment and Biopartnering Conference.
Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an 18% increased risk of atrial fibrillation—an irregular, often rapid heart rate—in a study of middle-aged adults in Taiwan. The findings are published in the British Journal of Clinical Pharmacology.
› Verified 4 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
One person dies of it every 30 seconds, it rivals HIV and tuberculosis as the world's most deadly infection and the vast majority of its victims are under five years old.
Today, UK charity Action on Hearing Loss announces a major investment to fund a new project to develop medicines to treat age-related hearing loss and noise-induced hearing loss at BioTrinity 2016 – Europe's Leading Investment and Biopartnering Conference.
Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an 18% increased risk of atrial fibrillation—an irregular, often rapid heart rate—in a study of middle-aged adults in Taiwan. The findings are published in the British Journal of Clinical Pharmacology.
› Verified 4 days ago
| Entity Name | Morristown Pathology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922075886 PECOS PAC ID: 4981699717 Enrollment ID: O20040420000045 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
One person dies of it every 30 seconds, it rivals HIV and tuberculosis as the world's most deadly infection and the vast majority of its victims are under five years old.
Today, UK charity Action on Hearing Loss announces a major investment to fund a new project to develop medicines to treat age-related hearing loss and noise-induced hearing loss at BioTrinity 2016 – Europe's Leading Investment and Biopartnering Conference.
Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an 18% increased risk of atrial fibrillation—an irregular, often rapid heart rate—in a study of middle-aged adults in Taiwan. The findings are published in the British Journal of Clinical Pharmacology.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wenjing Wang, MD 166 Smoke Rise Rd, Basking Ridge, NJ 07920-3710 Ph: () - | Wenjing Wang, MD 302 Lauman Ave, Eagleville, PA 19403-1626 Ph: (610) 631-8167 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.
One person dies of it every 30 seconds, it rivals HIV and tuberculosis as the world's most deadly infection and the vast majority of its victims are under five years old.
Today, UK charity Action on Hearing Loss announces a major investment to fund a new project to develop medicines to treat age-related hearing loss and noise-induced hearing loss at BioTrinity 2016 – Europe's Leading Investment and Biopartnering Conference.
Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an 18% increased risk of atrial fibrillation—an irregular, often rapid heart rate—in a study of middle-aged adults in Taiwan. The findings are published in the British Journal of Clinical Pharmacology.
› Verified 4 days ago